Press Release Friday 22 June 2018
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Sativa Investments PLC
(“Sativa” or “the Company”)
Sativa agrees purchase of 100% of CBD product provider George Botanicals
Sativa Investments PLC (NEX:SATI), the UK’s only medicinal cannabis investment vehicle, has agreed to purchase, for £415,000, 100 per cent of George Botanicals Ltd, a UK-based manufacturer, wholesaler and distributor of wellness CBD products, following the Memorandum of Understanding announced by Sativa on Tuesday 17 April, 2018. The Company will pay £215,000 in cash and £200,000 in shares in Sativa at £0.04 per share.
The vendor is Carbon Managers Limited (“Carbon Managers”), of which Sativa’s Chief Executive Officer, Geremy Thomas, is the 100 per cent shareholder. Geremy Thomas and George Thomas are significant shareholders in Sativa and both are also Directors of Carbon Managers. Pursuant to the NEX Exchange Growth Market Rules for Issuers, the transaction would therefore constitute a related party transaction. Geremy Thomas is not involved in any of Sativa’s decision-making process in relation to this purchase.
Mark Blower, Executive Director of Sativa Investments, said: “There are 365,000 confirmed users of CBD oil in the UK today and the market over the next two years will be worth £100 million, according to the Cannabis Trades Association. George Botanicals is well-placed to gain a significant market share.”
The Directors of the Company accept responsibility for the contents of this announcement.
– Ends –
For further information please contact:
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
NEX Exchange Corporate Adviser
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
+44 (0) 20 7469 4630
Notes to Editors
Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.
The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa intends to acquire can either be public or private.
The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.
For more information on Sativa Investments, please visit: